GPD-1116

• Description :

  GPD-1116 is an orally active Phosphodiesterase (PDE) 4 and PDE1 inhibitor. GPD-1116 can reduce smoke-induced apoptosis of lung cells. GPD-1116 is effective in several disease models in animals, including emphysema, acute lung injury, chronic obstructive pulmonary disease (COPD), asthma and pulmonary hypertension[1].

• CAS Number :

  [690690-72-3]

• UNSPSC :

  12352005

• Target :

  Apoptosis; Phosphodiesterase (PDE)

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/gpd-1116.html

• Smiles :

  O=C1C2=C(C3=C(N1C4=CC=CC=C4)N=CC=C3)NN=C2CC5=CC=CC=C5

• Molecular Formula :

  C22H16N4O

• Molecular Weight :

  352.39

• References & Citations :

  [1]Nose T, et, al. Pharmacological Profile of GPD-1116, an Inhibitor of Phosphodiesterase 4. Biol Pharm Bull. 2016;39 (5) :689-98.|[2]Mori H, et, al. Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 strain. Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294 (2) :L196-204.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported